Title:

Trans-ancestry genome-wide association study identifies novel genetic mechanisms in rheumatoid
 arthritis

4

1

5 Authors:

Kazuyoshi Ishigaki^{1,2,3*}, Saori Sakaue^{1,2,4,5*}, Chikashi Terao^{6,7,8*}, Yang Luo^{1,2,5,9,10}, Kyuto Sonehara^{4,11}, 6 Kensuke Yamaguchi^{12,13}, Tiffany Amariuta^{1,2,5,9,10,14}, Chun Lai Too^{15,16}, Vincent A Laufer^{17,18}, Ian C 7 Scott^{19,20}, Sebastien Viatte^{21,22,35}, Meiko Takahashi²³, Koichiro Ohmura²⁴, Akira Murasawa²⁵, Motomu 8 Hashimoto^{26,27}, Hiromu Ito^{26,28}, Mohammed Hammoudeh²⁹, Samar Al Emadi²⁹, Basel K Masri³⁰, Hussien 9 Halabi³¹, Humeria Badsha³², Imad W Uthman³³, Xin Wu³⁴, Li Lin³⁴, Ting Lin³⁴, Darren Plant²¹, Anne 10 Barton^{21,35}, Gisela Orozco^{21,35}, Suzanne MM Verstappen^{35,36}, John Bowes^{21,35}, Alexander J MacGregor³⁷, 11 Suguru Honda^{38,39}, Masaru Koido⁶, Kohei Tomizuka⁶, Yoichiro Kamatani^{6,40}, Hiroaki Tanaka⁴¹, Eiichi 12 Tanaka^{38,39}, Akari Suzuki¹³, Yuichi Maeda^{11,42,43}, Kenichi Yamamoto^{4,44,45}, Satoru Miyawaki⁴⁶, Gang Xie⁴⁷, 13 Jinyi Zhang^{47,48}, Chris Amos⁴⁹, Ed Keystone⁵⁰, Gertjan Wolbink⁵¹, Irene van der Horst-Bruinsma⁵², Jing 14 Cui⁹, Katherine P Liao^{9,10,53}, Robert J Carroll⁵⁴, Hye-Soon Lee^{55,56}, So-Young Bang^{55,56}, Katherine A 15 Siminovitch^{47,57}, Niek de Vries⁵², Lars Alfredsson⁵⁸, Solbritt Rantapää-Dahlqvist⁵⁹, Elizabeth W Karlson⁹, 16 Sang-Cheol Bae^{55,56}, Robert P Kimberly⁶⁰, Jeffrey C Edberg⁶⁰, Xavier Mariette⁶¹, Tom Huizinga⁶², 17 Philippe Dieudé^{63,64}, Matthias Schneider⁶⁵, Martin Kerick⁶⁶, Joshua C Denny^{54,67,68}, The Biobank Japan 18 Project⁶⁹, Koichi Matsuda^{70,71}, Keitaro Matsuo^{72,73}, Tsuneyo Mimori²⁴, Fumihiko Matsuda²³, Keishi Fujio⁷⁴, 19 Yoshiya Tanaka⁴¹, Atsushi Kumanogoh^{11,21,42,43}, Matthew Traylor⁷⁵, Cathryn M Lewis^{75,76}, Stephen 20 Eyre^{21,35}, Huji Xu^{34,77,78}, Richa Saxena⁵, Thurayya Arayssi⁷⁹, Yuta Kochi^{12,13}, Katsunori Ikari^{38,80,81}, 21 Masayoshi Harigai^{38,39}, Peter K Gregersen⁸², Kazuhiko Yamamoto¹³, S. Louis Bridges, Jr^{83,84}, Leonid 22 Padyukov¹⁶, Javier Martin⁶⁶, Lars Klareskog¹⁶, Yukinori Okada^{4,11,44,85,86**}, Soumya 23 Ravchaudhuri^{1,2,5,9,10,21**} 24

25 (*these authors contributed equally; **corresponding authors)

- 26
- 27 **Corresponding authors:** Yukinori Okada and Soumya Raychaudhuri.

28 Affiliations:

- 1, Center for Data Sciences, Brigham and Women's Hospital and Harvard Medical School, Boston, MA,
 USA.
- 2, Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical
- 32 School, Boston, MA, USA.
- 33 3, Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama,
- Japan.
- 4, Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
- ³⁶ 5, Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA,
- 37 USA.
- ³⁸ 6, Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences,
- 39 Yokohama, Japan.
- 40 7, Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan.
- 8, The Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka,
- 42 Shizuoka, Japan.
- 43 9, Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and
- 44 Women's Hospital and Harvard Medical School, Boston, MA, USA.
- 10, Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
- ⁴⁶ 11, Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary
- 47 Research Initiatives, Osaka University, Suita, Japan.
- 12, Department of Genomic Function and Diversity, Medical Research Institute, Tokyo Medical and
- 49 Dental University, Tokyo, Japan.
- 13, Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama,
 Japan.
- ⁵² 14, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- ⁵³ 15, Immunogenetics Unit. Allergy and Immunology Research Center. Institute for Medical Research.
- 54 National Institutes of Health Complex. Ministry of Health, Malaysia.

- 16, Department of Medicine, Division of Rheumatology, Karolinska Institutet and Karolinska University
- 56 Hospital, Stockholm, Sweden.
- 17, Department of Clinical Immunology and Rheumatology, University of Alabama at Birmingham School
- 58 of Medicine, AL, USA.
- ⁵⁹ 18, Michigan Medicine Department of Pathology, MI, USA.
- ⁶⁰ 19, Haywood Academic Rheumatology Centre, Haywood Hospital, Midlands Partnership NHS
- ⁶¹ Foundation Trust, Burslem, UK.
- ⁶² 20, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
- 63 21, Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological
- 64 Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of
- 65 Manchester, Manchester Academic Health Science Centre, Manchester, UK.
- 66 22, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, The
- 67 University of Manchester, UK.
- ⁶⁸ 23, Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- ⁶⁹ 24, Department of Rheumatology and Clinical immunology, Graduate School of Medicine, Kyoto
- 70 University, Kyoto, Japan.
- 25, Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan.
- 26, Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of
- 73 Medicine, Kyoto, Japan.
- 27, Department of Clinical Immunology, Graduate School of Medicine, Osaka City University, Osaka,
- 75 Japan.
- ⁷⁶ 28, Department of Orthopaedic Surgery, Kurashiki Central Hospital, Okayama, Japan.
- 29, Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
- ⁷⁸ 30, Department of Internal Medicine, Jordan Hospital, Amman, Jordan.
- ⁷⁹ 31, Rheumatology Division, Department of Internal Medicine, King Faisal Specialist Hospital and
- 80 Research Center, Jeddah6, Saudi Arabia.
- ⁸¹ 32, Dr. Humeira Badsha Medical Center, Emirates Hospital, Dubai, United Arab Emirates.

- ⁸² 33, Department of Rheumatology, American University of Beirut, Beirut, Lebanon.
- ⁸³ 34, Department of Rhuematology and Immunology, Shanghai Changzeng Hospital, The Second Military
- ⁸⁴ Medical University, China.
- 35, NIHR Manchester Biomedical Research Centre, Manchester University Foundation Trust,
- 86 Manchester, UK.
- ⁸⁷ 36, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Division of
- ⁸⁸ Musculoskeletal and Dermatological Sciences, the University of Manchester, Manchester, UK.
- ⁸⁹ 37, Norwich Medical School, University of East Anglia, NR4 7UQ. UK.
- ⁹⁰ 38, Institute of Rheumatology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
- 39, Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University
- 92 School of Medicine, Tokyo, Japan.
- ⁹³ 40, Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences,
- ⁹⁴ Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- ⁹⁵ 41, The First Department of Internal Medicine, School of Medicine, University of Occupational and
- 96 Environmental Health Japan, Kitakyushu, Japan.
- 42, Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of
- 98 Medicine, Suita, Japan.
- ⁹⁹ 43, Department of Immunopathology, Immunology Frontier Research Center (WPI-IFReC), Osaka
- 100 University, Suita, Japan.
- ¹⁰¹ 44, Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka
- 102 University, Suita, Japan.
- ¹⁰³ 45, Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
- ¹⁰⁴ 46, Department of Neurosurgery, Faculty of Medicine, the University of Tokyo, Tokyo, Japan.
- 105 47, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada.
- 106 48, Department of Medicine, University of Toronto, Toronto, Canada.
- 107 49, Baylor College of Medicine, Houston, TX, USA.
- ¹⁰⁸ 50, University of Toronto, Toronto, Canada.

- ¹⁰⁹ 51, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center (ARC), Reade,
- Amsterdam, The Netherlands.
- 52, Dept Rheumatology, Amsterdam University Medical Centers, AMC & ARC, Amsterdam, The
- 112 Netherlands.
- 53, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare
- 114 System, Boston, MA, USA.
- 115 54, Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA.
- 116 55, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
- ¹¹⁷ 56, Hanyang University Institute for Rheumatology Research, Seoul, Korea.
- ¹¹⁸ 57, Departments of Medicine and Immunology, University of Toronto, Toronto, Canada.
- 119 58, Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- ¹²⁰ 59, Dept of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden.
- 60, Center for Clinical and Translational Science, Division of Clinical Immunology and Rheumatology,
- 122 Department of Medicine, University of Alabama at Birmingham, AL, USA.
- 123 61, Department of Rheumatology, Université Paris-Saclay, Assistance Pubique Hôpitaux de Paris,
- 124 Hôpital Bicêtre, INSERM UMR1184, Le Kremlin Bicêtre, France.
- 125 62, Leiden University Medical Center, Lieden, The Netherlands.
- 126 63, University of Paris, Paris, France.
- 127 64, Department of Rheumatology, INSERM U1152, Hôpital Bichat-Claude Bernard, APHP, Paris,
- 128 France.
- 129 65, Department of Rheumatology & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University,
- 130 Düsseldorf, Germany.
- 131 66, Institute of Parasitology and Biomedicine Lopez-Neyra, CSIC, Granada, Spain.
- 132 67, All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, MD, USA.
- 133 68, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
- 134 69, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

- 135 70, Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The
- 136 University of Tokyo, Tokyo, Japan.
- 137 71, Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical
- Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- 139 72, Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer
- ¹⁴⁰ Center Research Institute, Nagoya, Aichi, Japan.
- ¹⁴¹ 73, Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya,
- 142 Aichi, Japan.
- ¹⁴³ 74, Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo,
- 144 Japan.
- 145 75, Department of Medical & Molecular Genetics, King's College London, London, UK.
- ¹⁴⁶ 76, Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK.
- ¹⁴⁷ **77**, School of Clinical Medicine Tsinghua University, Beijing, China.
- ¹⁴⁸ 78, Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
- ¹⁴⁹ 79, Department of Internal Medicine, Weill Cornell Medicine-Qatar, Education City, Doha, Qatar.
- 150 80, Department of Orthopedics, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- 151 81, Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women's Medical
- 152 University, Tokyo, Japan.
- 153 82, Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institutes for Medical
- 154 Research, Northwell Health, Manhasset, NY, USA.
- 155 83, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
- 156 84, Division of Rheumatology, Weill Cornell Medicine, New York, NY, USA.
- 157 85, Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
- 158 86, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan.

160 Abstract

161	Trans-ancestry genetic research promises to improve power to detect genetic signals, fine-mapping
162	resolution, and performances of polygenic risk score (PRS). We here present a large-scale genome-wide
163	association study (GWAS) of rheumatoid arthritis (RA) which includes 276,020 samples of five ancestral
164	groups. We conducted a trans-ancestry meta-analysis and identified 124 loci ($P < 5 \ge 10^{-8}$), of which 34
165	were novel. Candidate genes at the novel loci suggested essential roles of the immune system (e.g.,
166	TNIP2 and TNFRSF11A) and joint tissues (e.g., WISP1) in RA etiology. Trans-ancestry fine mapping
167	identified putatively causal variants with biological insights (e.g., LEF1). Moreover, PRS based on trans-
168	ancestry GWAS outperformed PRS based on single-ancestry GWAS and had comparable performance
169	between European and East Asian populations. Our study provides multiple insights into the etiology of
170	RA and improves genetic predictability of RA.

172 Main text

Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks the synovium 173 in the joints, leading to chronic tissue inflammation, joint destruction, and disability. While recent 174 therapeutic developments now alter the course of disease, RA mechanisms have yet to be fully 175 elucidated and a cure has yet to be identified. RA can be divided into two major subtypes (seropositive 176 and seronegative RA) based on the presence or absence of RA-specific serum antibodies (rheumatoid 177 factor or anti-citrullinated peptide antibodies)¹. Since RA is highly heritable²⁻⁴, genetic research has the 178 potential to advance our understanding of its pathology. Indeed, previous studies successfully identified 179 candidates of causal alleles, genes, pathways, and cell types^{2,5–7}. For example, previous studies 180 suggested that CD4⁺ effector T cells play a central role and the T cell receptor signaling pathway drives 181 autoimmunity in RA^{7-10} . 182

Trans-ancestry genetic research has multiple advantages over single-ancestry analysis. First, 183 genome-wide association study (GWAS) in a single ancestry can be underpowered to detect signals 184 from a causal allele with low allele frequency in that ancestry. As notable examples, the causal alleles 185 can be ancestry-specific, as shown in studies for other complex diseases^{11–13}. Having multiple ancestries 186 with different allele frequency spectrum can improve the power. Second, single-ancestry GWAS are 187 hampered by the specific linkage disequilibrium (LD) structure in that ancestry, which could obscure the 188 ability to effectively fine-map an associated locus^{14,15}. Trans-ancestry GWAS can improve fine-mapping 189 resolution by leveraging the distinct LD structures in each ancestry^{15–17}. Third, PRS generally has limited 190 transferability across ancestries. For example, when the PRS model is developed based on GWAS in 191 European (EUR) populations, PRS performs poorly in non-EUR populations¹⁸. PRS based on trans-192 ancestry GWAS can potentially improve its performance in multiple ancestries^{19,20}; this is a clinically 193 important topic since PRS can benefit patients via precision medicine. Although many RA genetic studies 194 were conducted in non-EUR populations^{2,3,17,21-24}, they were relatively small in the sample sizes, and 195 much larger research efforts have focused on EUR populations^{6,25–32}. 196

Here, we report a large-scale trans-ancestry GWAS of RA, including individuals of EUR, East
 Asian (EAS), African (AFR), South Asian (SAS), and Arabian (ARB) ancestries. While seropositive and

seronegative RA are associated with phenotypic differences, they have shared heritability³³, and their 199 risk alleles appear to be similar outside of the major histocompatibility complex (MHC) locus³⁴. Therefore, 200 we initially focused on all RA, and then we restricted cases to seropositive patients. After identifying 201 novel loci, we conducted fine-mapping to elucidate potential molecular mechanism of risk alleles. We 202 examined the extent to which genetic signals are shared across ancestries while also investigating 203 ancestry-specific genetic signals. We developed PRS models using our GWAS results and compared 204 their performances across all ancestries. Our study provides multiple insights into the etiology of RA and 205 highlights the importance and further needs of diversifying the ancestral background of GWAS 206 participants. 207

208

209 **RESULTS**

210 Trans- and single-ancestry GWAS

We included 37 cohorts comprising 35,871 RA patients and 240,149 control individuals of EUR, EAS, 211 AFR, SAS, and ARB ancestry (Figure 1a; Supplementary Table 1 and 2); 22,350 cases and 74,823 212 controls in 25 EUR cohorts; 11.025 cases and 162,608 controls in eight EAS cohorts; 999 cases and 213 1,108 controls in two AFR cohorts; 986 cases and 1,258 controls in one SAS cohort; and 511 cases and 214 352 controls in one ARB cohort. RA-specific serum antibodies were measured in 31,963 (89%) of cases; 215 among them 27,448 (86%) were seropositive and 4,515 (14%) were seronegative (Supplementary 216 Table 1; Methods). To confirm the diversity of ancestral backgrounds, we projected each individual's 217 genotype into principal component (PC) space which was calculated using all individuals in 1000 218 Genomes Project Phase 3 (1KG Phase3). We further conducted uniform manifold approximation and 219 projection (UMAP) using their top 20 PC scores. This revealed finer scale ancestral structure, and 220 confirmed that our study represented many 1KG Phase 3 ancestries (Figure 1b and 1c; Extended Data 221 Figure 1). 222

After quality control and imputation, we conducted GWAS in each cohort by logistic regression (Methods). We calculated genomic inflation using all variants outside of the MHC locus and observed little evidence of statistical inflation (mean of lambda = 1.01; S.D = 0.04; **Supplementary Table 1**).

Primary analysis included all cases, while we restricted cases to seropositive patients in a secondary
 analysis.

We then conducted a meta-analysis using all cohorts across five ancestries by the inverse-228 variance weighted fixed effect model (trans-ancestry GWAS). We observed almost identical effect sizes 229 between this trans-ancestry GWAS and the previously reported 100 RA risk alleles² (Pearson's r = 0.98230 and $P = 2.8 \times 10^{-82}$; Supplementary Figure 1; Supplementary Table 3). We detected 108 genome-wide 231 significant loci ($P < 5 \times 10^{-8}$) in this trans-ancestry study: 106 autosomal loci and two loci on the X 232 chromosome (Supplementary Table 4 and 5). For ancestries with multiple cohorts (EUR, EAS, and 233 AFR), we also conducted a meta-analysis within each ancestry by the same strategy (EUR-, EAS-, and 234 AFR-GWAS). EUR-GWAS identified three additional autosomal loci which were not significant in trans-235 ancestry GWAS (Supplementary Table 4). GWAS of seropositive RA additionally detected 13 236 autosomal loci (Supplementary Table 4). In total, we detected significant signals at 122 autosomal loci 237 outside of the MHC locus and two loci on the X chromosome (Supplementary Table 4 and 5; we 238 provided Manhattan and QQ plots in **Supplementary Figure 2**). Among these 122, 34 autosomal loci 239 were novel (Table 1). Notably, 25 novel loci had not been implicated in any other autoimmune diseases 240 (Supplementary Table 4; Methods). 241

To quantify the heritability, we analyzed our GWAS results using stratified-linkage disequilibrium score regression (S-LDSC)¹⁰ (**Supplementary Table 2**). Since S-LDSC assumes GWAS has samples from a single ancestral background and a sufficient sample size, we restricted this analysis to EUR- and EAS-GWAS. The heritability explained by non-MHC common variants was similar between EUR and EAS; the liability scale heritability was 0.14 (S.E. = 0.01) for EUR and 0.13 (S.E. = 0.01) for EAS (**Methods**). LDSC also confirmed that the amount of potential bias in the GWAS results was minimal; LDSC's intercept = 1.03 for EUR and 1.02 for EAS (**Supplementary Table 2**).

249

250 Fine-mapping analysis

We fine-mapped these 122 autosomal loci using approximate Bayesian factor (ABF)³⁵ (**Methods**). The 95% credible sets included only one variant at seven loci (**Figure 2a**). Of these seven, six have not been

reported in prior studies that conducted trans-ancestry fine-mapping of RA^{17,36} (Supplementary Table 253 6). The 95% credible sets included less than ten variants at 43 loci (Figure 2a). We identified 35 fine-254 mapped variants with posterior inclusion probability (PIP) greater than 0.5, which agree with and largely 255 subsume prior fine-mapping results^{6,17,36}; in addition, nine novel loci are represented (**Figure 2b**; 256 Supplementary Figure 3; Supplementary Table 6). The proportion of non-synonymous variants was 257 higher in the credible set variants with high PIP (PIP > 0.5) than low PIP (odds ratio (OR) = 9.3; one-258 sided Fisher exact test *P* = 0.02; Figure 2c). 259 We quantified the 95% credible set variants within open chromatin regions in 18 hematopoietic 260 populations using gchromVAR software³⁷. Consistent with previous analyses, we observed the strongest 261

enrichment in CD4⁺ T cells ($P = 5.4 \times 10^{-4}$; **Extended Data Figure 2**). For example, rs58107865 at the

LEF1 locus (PIP > 0.99), rs7731626 at the ANKRD55 locus (PIP > 0.99), and rs10556591 at the ETS1

locus (*PIP* = 0.84) are located within CD4⁺ T cell-specific open chromatin regions (Z score > 2;

Supplementary Table 6; Methods). Among them, rs58107865 is a novel risk variant and suggested the
 importance of regulatory T cells (T-reg) in RA biology (Figure 2d); LEF1 synergizes with FOXP3 to
 reinforce the gene networks essential for T-regs³⁸. These results recapitulated a critical role of CD4⁺ T
 cells, especially T-regs, in RA biology.

As expected, compared with single-ancestry GWAS, trans-ancestry GWAS produced smaller sized credible sets and higher *PIP* (one-sided paired Wilcoxon text $P < 3.1 \times 10^{-11}$ and $< 1.1 \times 10^{-9}$, respectively) (**Figure 2a**; **Supplementary Figure 3**). For example, the *WDFY4* locus included 6,391 variants in the EUR 95% credible set, 64 variants in the EAS set, but only one in the trans-ancestry set, a missense variant of *WDFY4* (rs7097397; R1816Q; **Figure 2e**). Using a down-sampling experiment, we confirmed that this benefit was due to diversified LD structures as well as the increased sample size (**Supplementary Figure 3; Supplementary Note**).

276

277 Conditional analysis

We conducted conditional analyses in each cohort to explore associations independent from the lead variants and meta-analyzed the results using the same strategy. We detected 24 independent signals at

21 loci ($P < 5.0 \times 10^{-8}$; **Supplementary Table 7**). Consistent with previous results^{6,31}, we observed the largest number of independent associations at the *IL2RA*, *TYK2*, and *TNFAIP3* loci, where we observed three independent alleles (**Extended Data Figure 3**). The first and second lead variants at the *TYK2* locus were missense variants predicted to have damaging effects on *TYK2* protein function (SIFT score

284 < 0.01; Supplementary Table 8).</p>

In the IL6R locus, the conditional analysis identified two variants, rs12126142 (the first lead 285 variant) and rs4341355 (the second lead variant), that were weakly correlated with each other but 286 independently associated with RA (r^2 = 0.23 and 0.15 in EUR and EAS of 1KG Phase 3, respectively; 287 Supplementary Table 7). Interestingly, their protective alleles (rs12126142-A and rs4341355-C) almost 288 always create a haplotype with the risk allele of the other variant (**Extended Data Figure 4**). Hence, the 289 conditional analysis disentangled the independent yet mutually attenuating signals (Figure 3a). By 290 analyzing expression quantitative trait loci (eQTL) and splicing quantitative trait loci (sQTL) in three 291 immune cells from Blueprint consortium (CD4⁺ T cells, monocytes, and neutrophils)³⁹, we found that 292 rs12126142 and rs4341355 are likely to affect *IL6R* transcripts via different mechanisms. GWAS signals 293 conditioned on rs4341355 colocalized with sQTL signals in monocytes (posterior probability of 294 colocalization estimated by coloc software⁴⁰ (PP_{coloc}) > 0.99; Figure 3b; Supplementary Table 9); this 295 sQTL signal corresponds to a previously-reported splicing isoform of soluble IL6R⁴¹. On the other hand, 296 GWAS signals conditioned on rs12126142 colocalized with eQTL signals in CD4⁺ T cells ($PP_{coloc} = 0.97$; 297 Figure 3b; Supplementary Table 9). Therefore, our results suggested that both splicing and total 298 expression of *IL6R* independently influence the RA genetic risk. 299

Our conditional analyses also suggested interesting biology at the *PADI4-PADI2* locus. We found two independent associations at this locus: esv3585367 (the first lead variant at a *PADI4* intron) and rs2076616 (the second lead variant at a *PADI2* intron), consistent with previous studies^{17,42} (**Figure 4a**; **Supplementary Table 7**). In sQTL results from the Blueprint consortium³⁹, both *PADI4* and *PADI2* sQTL signals in neutrophils were colocalized with corresponding GWAS associations ($PP_{coloc} = 0.98$ and 0.79, respectively; **Supplementary Table 9**), suggesting that alternative splicing of *PADI4* and *PADI2* likely increases the RA risk.

PADI4 is critical for RA because it encodes an enzyme that citrullinates proteins, the main target 307 for autoantibody in RA^{23,43–45}. However, unlike *IL6R* with two functionally distinct isoforms⁴¹, full picture of 308 PADI4 splicing isoforms has not been extensively studied. To elucidate detailed molecular biology at the 309 PADI4 locus, we generated long-read sequencing datasets and inspected full-length PADI4 transcripts. 310 We identified a novel and probably non-functional splice isoform that produces a truncated protein-311 arginine deiminase (PAD) domain, an essential catalytic domain with two calcium-binding sites⁴⁶ (Figure 312 4b). Next, we differentially quantified PADI4 isoforms using RNA-seq data from 105 Japanese donors⁵. 313 We found that the risk allele (esv3585367-A) was associated with the decrease of the non-functional 314 novel isoform and the increase of the functionally intact isoform (Figure 4c). Notably, the allelic effect on 315 the total expression, which had been conventionally used for eQTL studies, was not predictive of that on 316 the functional isoform (the right panel in **Figure 4c**). Together, our analysis provided a novel genetic 317 mechanism of PADI4 and highlighted the importance of thoroughly investigating splice isoforms at the 318 risk loci using long-read sequencing. 319

320

321 Candidate causal genes at the associated loci

We next inferred the possible molecular consequences of all 148 detected variants: 124 lead variants (including two variants on the X chromosome) and 24 secondary variants detected by the conditional analysis.

We first focused on coding variants in LD with the lead variants in this GWAS ($r^2 > 0.6$ both in 325 EUR and EAS samples in 1KG Phase 3; Methods). We found missense variants that may drive genetic 326 signals at two novel loci (Table 1: Supplementary Table 8). An example is rs2269495 (A313V of 327 TNIP2), in LD with a lead variant rs4690029 ($r^2 = 0.65$ and 0.89 in EUR and EAS of 1KG Phase 3, 328 respectively). rs2269495 is predicted to have a damaging effect on TNIP2 protein function (SIFT score = 329 0.02; Supplementary Table 8). The protein product of TNIP2 interacts with A20 (encoded by TNFAIP3) 330 and inhibits NF-kB activation induced by TNF. Mice with a defective mutant TNIP2 displayed intestinal 331 inflammation and hypersensitivity to experimental colitis⁴⁷. In addition, *TNIP1*, a homolog of *TNIP2*, was 332 identified as one of the novel loci in this GWAS (Supplementary Table 4). Together, these results 333

suggested that *TNIP1* and *TNIP2* are novel candidate causal genes of RA. Combined with the well established *TNFAIP3* locus (ref⁴⁸; **Supplementary Table 4**), these findings further supported the
 importance of the TNFAIP3-axis in RA biology.

We next inferred the possible molecular consequences using QTLs. We analyzed eQTL and 337 sQTL in three immune cells from Blueprint consortium (CD4⁺ T cells, monocytes, and neutrophils) and 338 multiple tissues from GTEx consortium^{39,49}. We found colocalizing QTL signals at 11 novel loci (PP_{coloc} > 339 0.7; Table 1; Supplementary Table 9 and 10). Several novel loci with colocalizing QTL signals 340 suggested the biology of the non-immune systems, including joint tissues. For example, the risk allele of 341 rs55762233 was associated with the increased expression of CILP2 (PPcoloc = 0.82), which encodes a 342 component of the cartilage extracellular matrix. Its homologous gene, CILP1, was recently reported as 343 one of the candidate autoantigens of RA⁵⁰. Therefore, the protein product of CILP2 might also have a 344 critical role in RA biology. 345

We then searched for other biologically plausible genes which might explain novel signals and found several genes whose importance was supported by previous knowledge (**Table 1**;

Supplementary Table 4). First, TNFRSF11A encodes RANK, a key regulator of osteoclast. Its ligand 348 RANKL has been investigated as a potential therapeutic target^{51,52}. TNFRSF11A is a causal gene for 349 several bone-related Mendelian disorders^{53–55}. Second, WISP1 encodes a protein essential for 350 osteoblast differentiation and bone formation^{56,57}. In addition, WISP1 is highly expressed in HLA-DRA^{hi} 351 inflammatory sublining fibroblasts, which are dramatically expanded and pathogenic in RA synovium⁵⁸. 352 Third, FLT3 encodes a tyrosine kinase that regulates hematopoiesis and knocking out of whose ligand 353 suppressed arthritis in model mice⁵⁹. A damaging variant of *FLT3* was suggested to be associated with 354 RA ($P = 4.3 \times 10^{-4}$) and other autoimmune diseases⁶⁰. 355

356

357 Differences and similarities of genetic risk across ancestries

We next searched for ancestry-specific signals at 122 autosomal loci. We defined ancestry-specificity when the lead variant in each locus is monomorphic in EUR or EAS samples of 1KG Phase 3. We found five EUR-specific signals: rs2476601 (a *PTPN22* missense variant), rs9826420 located in *STAG1*

intronic region, rs7943728 (a FADS2 eQTL), and rs34536443 and rs12720356 (both TYK2 missense 361 variants). EAS-GWAS also identified an EAS-specific signal at the TYK2 locus: rs55882956, another 362 TYK2 missense variant. We thus detected two EUR-specific and one EAS-specific signal at the TYK2 363 locus (Extended Data Figure 5). All these ancestry-specific signals were also reported by previous 364 studies^{2,25,61}. This study was underpowered to detect specific signals in non-EUR and non-EAS 365 ancestries (Supplementary Figure 4 and Supplementary Note). Although ancestry-specific signals are 366 relatively few, they include predominantly large effect size variants, many of which are missense, and 367 hence they are valuable resources to understand the etiology of RA. 368

Although we found these ancestry-specific signals, this study showed that genetic signals are 369 generally shared across ancestries. We compared effect sizes between EUR-GWAS with non-EUR-370 GWASs at the 30 fine-mapped variants (PIP > 0.5; **Methods**). We found that the effect sizes were

strongly correlated among five ancestries (Pearson's r = 0.56-0.91; Supplementary Figure 5; 372

Supplementary Note). In addition, we targeted genome-wide variants and tested the trans-ancestry 373 genetic correlation between EUR- and EAS-GWAS using popcorn software⁶² (we restricted this analysis 374 to EUR- and EAS-GWAS to avoid a biased correlation estimate caused by the small sample size). We 375 again found a strong correlation (0.64 (S.E.=0.08); $P = 4.4 \times 10^{-17}$; P value reported is for a test that the 376 correlation is different from 0). 377

378

371

Genetic risk differences between seropositive and seronegative RA 379

The presence or absence of autoantibodies (rheumatoid factor and anti-citrullinated peptide antibodies) 380 defines two major subgroups of RA: seropositive and seronegative RA¹. We tested the differences in 381 genetic signals between them at the 122 significant autosomal loci. Although their effect sizes were 382 significantly correlated in general (Pearson's r = 0.76; $P = 3.2 \times 10^{-23}$), we found significant heterogeneity 383 in effect size estimates at the nine loci: CCR6, CTLA4, NFKBIE-TMEM151B, PADI4, PTPN22, RAD51B, 384 SMIM20-RBPJ, TNFRSF14-AS1, and UBASH3A (P_{het} < 0.05/122; Extended Data Figure 6). Effect size 385 estimates were larger in seropositive RA at all the nine loci, and these findings suggested etiological 386 differences between seropositive and seronegative RA. For example, CCR6 has critical roles in B cell 387

antibody production^{63,64}. Together, these findings suggested generally shared genetic risks between
 seropositive and seronegative RA outside of the MHC locus, although substantial differences exist
 around biologically relevant genes.

391

Genome-wide distributions of heritability

To acquire insights into RA biology, we estimated the heritability enrichments within gene regulatory 393 regions using S-LDSC¹⁰, a method to infer the genome-wide distribution of all causal variants irrespective 394 of their effect sizes. We again restricted this analysis to EUR- and EAS-GWAS. We utilized 707 IMPACT 395 regulatory annotations, which reflect comprehensive cell-type-specific transcription factor (TF) 396 activities⁶⁵. Briefly, IMPACT probabilistically annotates each nucleotide genome-wide on a scale from 0 397 to 1, and we considered genomic regions scoring in the top 5% of each annotation. We detected 398 significant enrichments in 114 annotations in either of EUR and EAS ($P < 0.05/707 = 7.1 \times 10^{-5}$; Figure 399 5a and Supplementary Table 11). The amount of heritability explained by each annotation was highly 400 concordant between EUR and EAS (Pearson's r = 0.92; $P = 1.3 \times 10^{-290}$; Figure 5b), and we did not 401 observe significant heterogeneities between EUR and EAS estimates ($P_{het} > 0.05/707 = 7.1 \times 10^{-5}$). 402 Among annotations with significant enrichments, the one which explained the largest fraction of EUR 403 heritability was CD4⁺ T cell T-bet annotation (90%; S.E. = 11%). This annotation explained 94% (S.E. = 404 12%) of EAS heritability consistent with analyses on previous GWAS results⁶⁶. Although four out of 114 405 significant annotations were derived from non-immune cells, controlling the effect of CD4⁺ T cell T-bet 406 annotation canceled out all four enrichments. We also analyzed 396 histone mark annotations, but they 407 were less enriched in RA heritability than CD4⁺ T cell T-bet annotation (Extended Data Figure 7; 408 Supplementary Table 12; Supplementary Note). In addition to identifying candidate critical TFs in RA 409 pathology, these results also suggested that the distribution of causal variants is shared between EUR 410 and EAS. 411

We next tested whether the findings in S-LDSC analysis can be recapitulated in fine-mapped variants from genome-wide significant loci. We analyzed credible set variants and found that high *PIP* variants (> 0.5) were enriched in high IMPACT score variants for CD4⁺ T cell T-bet annotation (> 0.5),

compared with low *PIP* variants (**Figure 2c**; **Extended Data Figure 8**; OR = 8.7; one-sided Fisher exact test $P = 1.5 \times 10^{-4}$). We found six variants which possess high *PIP* and high IMPACT score, and one of them was a novel association at the intronic region of *LEF1* (rs58107865; **Supplementary Table 6**). Together, both polygenic and fine-mapped signals support the critical roles of CD4⁺ T cell's T-bet activity in RA pathology.

420

421 **PRS performance across five ancestries**

Our results showed that trans-ancestry GWAS can detect causal variants more efficiently than single-422 ancestry GWAS and these causal variants are strongly enriched within the CD4⁺ T cell T-bet annotation. 423 Therefore, we hypothesized that trans-ancestry GWAS and CD4⁺ T cell T-bet annotation can improve 424 PRS performances in non-EUR populations. To test this, we developed PRS models with six different 425 conditions using combinations of two components: i) two variant selection settings (we used all variants 426 or variants within the top 5% of the CD4⁺ T cell T-bet annotation and refer PRS based on each of them 427 as standard or functionally-informed PRS, respectively) and ii) three GWAS settings (we used trans-428 ancestry, EUR-, or EAS-GWAS and refer PRS based on each of them as trans-ancestry, EUR-, or EAS-429 PRS, respectively). We designed our study so that there were no overlapping samples; when we 430 evaluated the PRS performance in a given cohort, we re-conducted meta-analysis excluding that cohort 431 to develop PRS models (Figure 6a; Methods). We defined the performance of PRS by phenotypic 432 variance (pseudo- R^2) explained by PRS. We tested PRS performances using ten different P value 433 thresholds. We then selected the threshold with the best performance in each of the six PRS conditions 434 separately and utilized this threshold for the following analyses. 435

We first evaluated the variant selection settings used for PRS (standard and functionally-informed PRS). Consistent with our recent study⁶⁵, functionally-informed PRS improved the application of PRS constructed from different ancestries (EUR-PRS applied to non-EUR cohorts or EAS-PRS applied to non-EAS cohorts). Functionally-informed PRS increased R^2 by 2.7 fold on average, and we observed the improvement in 32 of 41 applications (one-sided sign test $P = 2.2 \times 10^{-4}$; **Figure 6b**; **Supplementary Table 13**). On the other hand, also consistent with our recent study⁶⁵, this improvement was relatively

small in the application of PRS constructed from the same ancestry (EUR-PRS applied to EUR cohorts 442 or EAS-PRS applied to EAS cohorts). Functionally-informed PRS increased R^2 by 1.3 fold on average. 443 and we observed the improvement in 21 out of 33 applications (one-sided sign test P = 0.08; Figure 6b; 444 Supplementary Table 13). PRS based on single-ancestry GWAS is affected by LD structures of GWAS 445 participants' ancestral backgrounds; this can reduce performance in prediction when we apply this PRS 446 to ancestries with different LD structures. These results confirmed that functionally-informed PRS can 447 mitigate this problem. Expectedly, for trans-ancestry PRS, which prioritizes causal variants over variants 448 solely associated through linkage, the benefit of functionally-informed PRS was very subtle; functionally-449 informed PRS increased R^2 only by 1.02 fold on average, and we observed the improvement only in 16 450 out of 37 applications (one-sided sign test P = 0.84; Figure 6b; Supplementary Table 13). Since CD4⁺ 451 T cell T-bet annotation always had beneficial or neutral effects on PRS performances, we used 452 functionally-informed PRS for the following analyses. 453

We next evaluated the GWAS settings used for PRS (trans-ancestry, EUR-, and EAS-PRS). Consistent with a recent study¹⁴, trans-ancestry PRS outperformed EUR-PRS and EAS-PRS; mean R^2 across 37 cohorts were 0.054, 0.041, and 0.022, in trans-ancestry, EUR-, and EAS-PRS, respectively (**Figure 6c**; **Supplementary Table 13**). Even for EUR cohorts for which the largest same-ancestry GWAS was available, trans-ancestry PRS outperformed EUR-PRS (one-sided paired Wilcoxon test *P* = 3.3 x 10⁻⁴; **Extended Data Figure 9**).

Finally, we compared the performance of trans-ancestry PRS in each population. The best 460 performance was found in the EUR cohorts (mean $R^2 = 0.059$; Figure 6c; Supplementary Table 13). 461 Strikingly, the PRS explained around half of the heritability by the non-MHC common variants, which is 462 the theoretical upper limitation (Supplementary Table 2). Even without the MHC region, we were able to 463 identify 9.9% of the EUR population with an inherited genetic predisposition that conferred three times 464 increased risk for RA (Figure 6d; Methods). The performance in the EAS cohorts was comparable with 465 the EUR cohorts; the mean R^2 was 0.057 (Wilcoxon test P = 0.67 compared with EUR cohorts), and we 466 were able to identify 5.5% of the EAS population with three times increased risk (Figure 6c and 6d). 467 However, we observed poor PRS performances in AFR, SAS, and ARB cohorts; the mean R^2 was 0.018 468

(Wilcoxon test *P* = 0.002 compared with EUR cohorts), and we were able to identify only 0.62% of these
 populations with three times increased risk (Figure 6c and 6d; Extended Data Figure 10). Together,
 trans-ancestry PRS exhibited the best performance in all ancestries in this study. However, the PRS
 performance in each ancestry was substantially affected by its sample size in this trans-ancestry GWAS,
 which firmly claims that it is imperative to increase the sample sizes of underrepresented ancestries to
 equalize genetic predictability of disease status.

475

476 **DISCUSSION**

This study identified 34 novel genetic signals and less than ten 95% credible sets at 43 loci. By using multiple functional annotations and prior immunological knowledge, we provided their potential molecular consequences. In addition to the novel loci, our comprehensive analyses provided novel biological interpretations to the known loci (e.g., the *IL6R* and *PADI4* loci). We conducted detailed analyses on ancestry specificity; although most genetic signals are shared across ancestries, we observed some ancestry-specific signals. We also found several candidates of critical TFs contributing to RA biology. This trans-ancestry study thus substantially advanced our understanding of RA biology.

We utilized the molecular QTL database to infer risk allele's gene regulatory function. This approach is a standard approach but has a limited ability to explore the allelic role comprehensively, as reported in a previous study⁶⁷. Since gene regulation is highly cell-type or cell-state specific, we need to extend the QTL experimental conditions to overcome this limitation. Single-cell QTL analysis may also represent a promising strategy⁶⁸. Another promising approach is inducing risk alleles in target cell populations using gene-editing techniques; previous studies reported the feasibility of this approach^{69–71}. Future advance in functional genetics would improve the biological insight from our GWAS.

Our study had insufficient power to detect significant signals for seronegative RA outside of the MHC region due to a limited sample size (4,515 cases of seronegative RA). Although we observed shared genetic risks between them (**Extended Data Figure 6**), this analysis was restricted to the loci detected in all RA or seropositive RA. To unveil the specific etiology of seronegative RA further, we need cohorts that are larger and have better representation of seronegative RA.

496	Poor PRS performance in non-EUR ancestries is becoming one of the major challenges in human
497	genetics. Conducting a trans-ancestry GWAS on a large scale is a promising strategy to mitigate this
498	issue. Indeed, trans-ancestry PRS performance in EAS cohorts was comparable to those in EUR
499	cohorts, demonstrating that this study mitigated inequality of genetic benefit at least partially (Figure 6c).
500	However, this study was underpowered to detect specific signals in non-EUR and non-EAS ancestries,
501	resulting in poor PRS performance in these ancestries. To overcome these limitations, we need further
502	efforts to diversify GWAS and increase sample sizes of underrepresented ancestries as in other common
503	complex diseases.

Table 1. Novel RA risk loci detected in this study. 504

Statistics in the GWAS setting with the lowest P values were provided (see Supplementary Table 4 for 505 details). The genomic coordinate is according to GRCh37. Predicted causal gene, predicted molecular 506 consequences using eQTL or non-synonymous variants (see Supplementary Table 8-10 for details); 507 OR, odds ratio (the effect allele is the alternative allele); L95, lower 95% confidence interval; U95, upper 508 95% confidence interval; allele freq., allele frequency of the effect allele. 509

									Allele	freq. in	1KG Ph	ase 3
Rs ID	Chr.	Position	Nearest gene	Predicted causal gene	OR	1.95	U95	P value	FAS	FUR	AFR	SAS
rs41269479	1	42 166 782	HIVEP3	NA	1 15	1 09	1 20	2 51E-08	0.26	0.28	0.08	0.42
rs41313373	1	92 940 411	GEI1	EVI5(eOTL)	1.10	1.00	1 16	1.08E-08	0.20	0.14	0.00	0.12
rs1188620266	1	235 800 357	GNG4	GNG4(eOTL)	0.91	0.88	0.94	2.06E-08	0.83	0.61	0.22	0.70
rs143259280	2	70 209 168	PCBP1-AS1	C2orf42(eQTL)	1 09	1.06	1 12	2.00E-00	0.00	0.32	0.89	0.32
10110200200		70,200,100	TAMM41	0201112(0Q12)	1.00	1.00		2.102.00	0.10	0.02	0.00	0.02
rs77574423	3	11,984,744	SYN2	SYN2(eQTL)	1.10	1.07	1.14	1.35E-08	0.56	0.72	0.57	0.74
rs62264113	3	127,292,333	TPRA1	TPRA1(eQTL)	0.92	0.89	0.95	4.66E-08	0.27	0.08	0.01	0.21
rs4687070	3	189,306,650	TPRG1, TP63	NA	1.15	1.09	1.20	6.07E-09	0.02	0.07	0.03	0.14
rs4690029	4	2 722 815	FAM193A	TNIP2(n A313\/)	0 94	0.92	0.96	2 83E-09	0 40	0 4 1	0.59	0 47
rs138066321	4	80 952 409	ANTXR2	ANTXR2(eOTL)	0.93	0.02	0.00	4 48E-10	0.38	0.45	0.00	0.32
rs58107865	4	109 061 618	I FF1	NA NA	0.00	0.80	0.00	4 92F-14	0.00	0.10	0.00	0.02
1000101000	·····	100,001,010	LINC00603		0.01	0.00	0.00	1.022 11	0.21	0.01	0.00	0.00
rs56787183	5	40,499,290	PTGER4	NA	0.85	0.80	0.90	2.15E-09	0.09	0.00	0.04	0.02
rs244468	5	142,604,421	ARHGAP26	NA	1.07	1.05	1.10	8.19E-09	0.79	0.51	0.41	0.60
rs1422673	5	150,438,988	TNIP1	NA	1.10	1.06	1.14	1.56E-08	0.50	0.19	0.39	0.29
rs113532504	6	15,195,682	LINC01108, JARID2	JARID2(eQTL)	1.10	1.07	1.14	3.42E-08	0.06	0.10	0.36	0.10
rs67318457	6	23,925,021	LOC105374972, NRSN1	NA	1.08	1.05	1.11	1.10E-08	0.14	0.27	0.37	0.05
rs940825	7	17,207,164	AGR3, AHR	NA	1.11	1.07	1.16	3.39E-08	0.18	0.12	0.05	0.06
rs182199544	7	27,084,581	SKAP2, HOXA1	HOXA3(eQTL), HOXA4(eQTL)	0.87	0.84	0.91	3.61E-09	0.01	0.08	0.36	0.03
rs6583441	7	50,361,874	IKZF1	NA	0.95	0.93	0.97	4.69E-08	0.53	0.47	0.33	0.41
rs6979218	7	99,893,148	CASTOR3, SPDYE3	PILRA(p.R78G) PVRIG(p.N81D)	1.09	1.06	1.12	2.24E-11	0.38	0.75	0.91	0.72
rs11777380	8	134,211,965	WISP1	NA	0.92	0.90	0.95	3.00E-10	0.17	0.32	0.08	0.19
rs911760	9	5,438,435	PLGRKT	NA	1.15	1.09	1.20	2.15E-08	0.23	0.19	0.33	0.28
rs734094	11	2,323,220	C11orf21, TSPAN32	NA	1.08	1.05	1.10	3.40E-08	0.19	0.40	0.43	0.45
rs1427749	12	46,370,116	SCAF11	ARID2(eQTL), SLC38A1(eQTL)	0.93	0.90	0.95	1.17E-08	0.89	0.80	0.91	0.95
rs61944750	13	28,634,933	FLT3	NA	0.91	0.88	0.94	1.69E-08	0.05	0.21	0.09	0.09
rs2147161	13	42,982,302	AKAP11, LINC02341	NA	1.10	1.06	1.13	2.73E-08	0.13	0.21	0.02	0.28
rs175714	14	75,981,856	JDP2, BATF	NA	0.94	0.92	0.96	4.14E-08	0.43	0.60	0.30	0.64
rs115284761	15	77,326,836	PSTPIP1	NA	0.91	0.89	0.94	1.71E-11	0.28	0.25	0.15	0.23
rs11375064	17	25,904,074	KSR1	NA	1.08	1.05	1.11	3.92E-08	0.44	0.60	0.53	0.47
rs591549	18	3,542,247	DLGAP1	NA	0.91	0.88	0.94	9.14E-09	0.35	0.68	0.42	0.61
rs371734407	18	60,009,634	TNFRSF11A	NA	1.10	1.06	1.14	4.14E-08	0.44	0.59	0.50	0.52
rs10415976	19	941,603	ARID3A	NA	0.92	0.90	0.95	2.90E-08	0.47	0.08	0.35	0.25
rs55762233	19	19,367,319	HAPLN4	CILP2(eQTL), COMP(eQTL), HAPLN4(eQTL), LPAR2(eQTL), SUGP1(eQTL), TM6SF2(eQTL), TSSK6(eQTL), YJEFN3(eQTL), ZNF101(eQTL)	1.10	1.07	1.14	1.43E-09	0.02	0.17	0.32	0.14
rs28373672	19	36,213,072	KMT2B	LIN37(eQTL)	0.93	0.91	0.96	3.33E-08	0.24	0.23	0.62	0.29
rs8106598	19	52,017,940	SIGLEC12, SIGLEC6	NA	1.08	1.05	1.11	3.12E-08	0.08	0.22	0.32	0.17



511

Figure 1. Diverse ancestral background in this GWAS participants.

(a) Study design of this GWAS. The total number of cases and controls are provided.

(b) PCA plot of all GWAS samples. We projected each individual's imputed genotype into a PC space

which was calculated using all individuals in 1KG Phase3. The samples are colored by its ancestry
 group.

(c) UMAP plots of all GWAS samples. We conducted UMAP analysis using their top 20 PC scores. The

- samples in a cohort were colored by the country/region-level group of that cohort (**Supplementary Table**
- **1**). When a cohort recruited participants from multiple countries, we did not plot its samples.



520

521 Figure 2. Fine-mapping analysis identified candidates of causal variants.

(a) Among 122 autosomal loci analyzed, we counted the number of loci whose 95% credible set size was
 in a specified range. The results from EAS-, EUR- and trans-ancestry GWAS are provided.

(b) The *PIP* of the lead variant and the size of 95% credible set at the 122 autosomal loci analyzed. The name of novel loci whose *PIP* was greater than 0.75 are labeled. We used trans-ancestry GWAS results.

(c) In each range of *PIP* (the total number of variants were provided on the top), we calculated the

proportion of non-synonymous variants or variants with high IMPACT score ($CD4^+$ T cell T-bet annotation > 0.5).

(d) A fine-mapped variant at the *LEF1* locus within CD4⁺ T cell specific open chromatin regions. *P* values
 of trans-ancestry GWAS are provided with dense view of immune cell ATAC-seq data (density indicate
 the read coverage) and vertebrate conservation data from UCSC genome browser

532 (http://genome.ucsc.edu).

(e) P values in the WDFY4 locus in EAS- and trans-ancestry GWAS. We provide r^2 between each variant

and the lead variant (rs7097397) by different colors. For trans-ancestry GWAS, we used intersection of

- LD variants in EUR and EAS ancestries.
- 536



538 Figure 3. Splicing and total expression of *IL6R* jointly contribute to RA risk.

(a) The 1st lead variant (rs12126142; red) and the 2nd lead variant (rs4341355; blue) are mutually
 attenuating their signals (controlling the effect of the other increased their signals). Conditional analysis
 was conducted in each cohort and the results were meta-analyzed using the inverse-variance weighted

- 542 fixed effect model. We used trans-ancestry GWAS results.
- (b) *P* values of sQTL signals of *IL6R* (phenotype id: ENSG00000160712.8.17_154422457 in Blueprint
- ⁵⁴⁴ dataset) and eQTL signals of *IL6R* (total expression of *IL6R*).
- We highlighted variants in LD with the lead variant by red or blue ($r^2 > 0.6$ in both EUR and EAS ancestries).
- 547



548 549

550 Figure 4. Splicing of *PADI4* contributes to RA risk.

(a) Conditional analyses identified two independent associations at the *PADI4* locus: esv3585367 (red) and rs2076616 (blue). We used trans-ancestry GWAS results. We highlighted variants in LD with the lead variant by red or blue ($r^2 > 0.6$ in both EUR and EAS ancestries).

(b) A novel *PADI4* splice isoform confirmed by long-read sequencing datasets. *PADI4*-novel, a novel
 isoform we identified. *PADI4*-201, a functional isoform. *PADI4-novel* has an elongation of exon 10 which
 leads to an early stop codon and a truncated PAD domain at the C-terminus. PAD domain is an essential
 catalytic domain⁴⁶, and highly conserved across other *PADI* genes.

(c) The total expression and the expression of three isoforms of *PADI4* were plotted with the imputed dosages of the risk allele (esv3585367-A). The isoform structures were shown in (b). We analyzed a RNA-seq dataset of 105 Japanese healthy individuals reported in a previous study⁵. We used peripheral blood leukocytes (neutrophils are its main component) and monocytes, both have high *PADI4* expression levels. *P* values from linear regression are provided. Within each boxplot, the horizontal lines reflect the median, the top and bottom of each box reflect the interquartile range (IQR), and the whiskers reflect the

- maximum and minimum values within each grouping no further than 1.5 x IQR from the hinge.
- 565



566

⁵⁶⁷ Figure 5. S-LDSC analysis suggested similar causal variant distributions in EUR- and EAS-GWAS.

- (a) EUR- and EAS-GWAS results were analyzed by S-LDSC using 707 IMPACT annotations. *P* value
- indicates significance of non-zero tau (per variant heritability) of each annotation. Each annotation was
 colored by its cell type category. Horizontal dashed line indicates Bonferroni-corrected *P* value threshold
- 571 $(0.05/707 = 7.1 \times 10^{-5}).$
- (b) The estimate and its 95% confidence interval of the heritability proportion explained by top 5% of
- ⁵⁷³ IMPACT annotations. When a heritability enrichment was significant ($P < 0.05/707 = 7.1 \times 10^{-5}$), that
- annotation was colored by the type of GWAS ("Both" indicates the annotation was significant both in 575 EUR- and EAS-GWAS).



577 578

Figure 6. Functional annotation and trans-ancestry GWAS improved PRS performances.

(a) The strategy of our PRS analysis. We utilized PRS based on three GWAS settings; two single ancestry PRS (EUR- and EAS-PRS) and a trans-ancestry PRS. Single ancestry PRS had two types of
 applications; same-ancestry application of PRS (EUR-PRS applied to EUR cohorts or EAS-PRS applied
 to EAS cohorts) and different-ancestry application of PRS (EUR-PRS applied to non-EUR cohorts or
 EAS-PRS applied to non-EAS cohorts). When we applied a PRS model to a cohort included in a GWAS
 setting, we re-conducted the meta-analysis excluding that cohort to avoid overlapped samples. The
 numbers of each application are provided.

(b) The improvements in PRS performance (*pseudo-R*²) by CD4⁺ T cell T-bet IMPACT annotation. Fold 586 change indicates R^2 in functionally-informed PRS divided by R^2 in the standard PRS. We compared three 587 conditions: same-ancestry application of single ancestry PRS (n=33), different-ancestry application of 588 single ancestry PRS (n=41), and trans-ancestry PRS (n=37). One-sided sign test P value is provided. 589 (c) The performance (liability-scale R²) of three different PRS models. The results of three PRS models 590 in all cohorts are shown on the left panel. The results of trans-ancestry PRS in three cohort groups are 591 shown on the right panel. The differences in R^2 were assessed by Wilcoxon test. In all conditions, CD4⁺ 592 T cell T-bet IMPACT annotation was utilized to select variants. 593

- (d) PRS distribution differences between case and controls. Trans-ancestry PRS with CD4⁺ T cell T-bet
 IMPACT annotation was used. In each cohort, PRS was scaled using mean and SD of the control
 samples, and individual level data were merged across cohorts in an ancestral group. For a given PRS
- value at the right tail of PRS distribution, we compared the case-control ratios between individuals whose
 PRS is higher than that value and individuals whose PRS is lower than that value, and calculated the
- PRS is higher than that value and individuals whose PRS is lower than that value odds ratio (OR). The PRS values with OR = 3 are shown by solid vertical lines.
- Within each boxplot, the horizontal lines reflect the median, the top and bottom of each box reflect the interquartile range (IQR), and the whiskers reflect the maximum and minimum values within each grouping no further than 1.5 x IOR from the binge
- grouping no further than 1.5 x IQR from the hinge.

603 Methods

604 Study participants

We included 35,871 RA patients and 240,149 control individuals of EUR, EAS, AFR, SAS, and ARB 605 ancestry from 37 cohorts (Supplementary Table 1). All RA cases fulfilled the 1987 American College of 606 Rheumatology (ACR) criteria⁷² or the 2010 ACR/the European League Against Rheumatism criteria⁷³. or 607 were diagnosed with RA by a professional rheumatologist. Among 35,871 patients, seropositivity status 608 was available for 31,963; 27,448 were seropositive and 4,515 were seronegative (Supplementary Table 609 1). We defined seropositivity as the presence of rheumatoid factor or anti-citrullinated peptide antibodies. 610 611 When a seropositive and seronegative GWAS has less than 50 cases, we excluded it from this study since GWAS with too few samples produces unstable statistics. All cohorts obtained informed consent 612 from all participants by following the protocols approved by their institutional ethical committees. We 613 have complied with all relevant ethical regulations. 614

615

616 **Genotyping and imputation**

Genotyping platform and all quality control (QC) parameters of each cohort were provided in 617 **Supplementary Table 1.** For QC of samples, we excluded those with (i) low sample call rate, (ii) closely 618 related individuals, and (iii) outliers in terms of ancestries identified by PCA using the genotyped samples 619 and all 1KG Phase 3 samples. Since 1KG Phase 3 does not include ARB samples, we did not exclude 620 individuals in ARB cohort based on ancestral outliers. For QC of genotypes, we excluded variants 621 meeting any of the following criteria: (i) low call rate, (ii) low MAF, and (iii) low P value for Hardy 622 Weinberg equilibrium (HWE). Post-QC genotype data of each cohort was pre-phased using Shapeit2 or 623 Eagle2 software. For EUR, AFR, and ARB cohorts, we conducted imputation with Minimac3 or Minimac4 624 software using the 1KG Phase 3 reference panel. For EAS and SAS cohorts, we conducted imputation 625 with Minimac3 or Minimac4 using a reference panel which were generated by merging 1KG Phase 3 626 panel and whole genome sequence (WGS) data of each population (Supplementary Table 1); we used 627 WGS data of 1,037 Japanese⁷⁴, 89 Korean⁷⁵, 7 Chinese⁷⁶ or 96 Malaysian individuals⁷⁷. For QC of 628 imputed genotype data, we excluded low imputation guality variants (imputation $r^2 < 0.3$) from each 629

cohort, excluded variants with minor allele count less than ten in the reference panel, and then we
 included variants which passed QC in at least five cohorts; we finally included 20,990,826 autosomal
 variants and 736,614 X chromosome variants. The genomic coordinate is according to GRCh37 in all
 analyses.

634

635 PCA and UMAP using all GWAS participants

To assess the ancestral background diversity of all GWAS participants, we projected them into the same 636 PC space based on their imputed genotype data. From variants which passed QC criteria in all 37 637 cohorts (imputation $r^2 \ge 0.3$), we first identified 12,196 independent imputed variants ($r^2 < 0.2$ in EUR 638 samples of 1KG Phase 3). Due to data access restrictions, we were not able to transfer raw imputed 639 genotype data across different institutes, and hence we were not able to conduct one PCA using all 640 individuals. Therefore, we first conducted PCA using these variants and all 1KG Phase3 samples, and 641 calculated the loadings of each variant for top 20 PCs. We then calculated each individual's PC scores 642 using these loadings and imputed dosage of our GWAS samples. We further conducted UMAP by umap 643 package in R using these top 20 PC scores (n neighbors = 30 and min dist = 0.8). 644

645

646 **Genome-wide** association analysis

We conducted GWAS in each cohort by a logistic regression model using PLINK2 software. We included 647 age, sex, and genotype PCs within each cohort as covariates (details of covariates were provided in 648 **Supplementary Table 1**). We then conducted meta-analysis using all cohorts by the inverse-variance 649 weighted fixed effect model as implemented in METAL (trans-ancestry GWAS). For ancestries with 650 multiple cohorts, we similarly conducted meta-analysis within each ancestry (EUR-, EAS-, and AFR-651 GWAS). When the seropositivity status was available, we also conducted GWAS only using seropositive 652 RA samples and controls. We defined a locus as a genomic region within ±1 Mb from the lead variant, 653 and we considered a locus as novel when it did not include any variants previously reported for RA. For 654 non-RA autoimmune diseases (systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, 655 dermatomyositis, juvenile dermatomyositis, and polymyositis), we used ±0.5 Mb window from the lead 656

657	variant. We defined reported variants as significant variants ($P < 5 \times 10^{-8}$) reported in the GWAS Catalog
658	(<u>https://www.ebi.ac.uk/gwas/;</u> e104_r2021-10-06) and those reported in previous literatures which we
659	searched manually. Since we need a unique analytical strategy for the MHC locus, we excluded the
660	MHC region (chr6:25Mb-35Mb) from this study, which will be reported in an accompanying project.
661	We performed stepwise conditional analysis within ± 1 Mb from the lead variant. We conducted
662	the same logistic regression model but including the dosages of the lead variants (index variants in the
663	first round of conditional analysis) as covariates in each cohort; when the lead variants did not exist in
664	post-QC imputed genotype data of a cohort (imputation $r^2 \ge 0.3$), we exclude that cohort from the
665	analysis. We then conducted meta-analysis using the same strategy, and identified the 2 nd lead variant.
666	We repeated these processes by sequentially adding the identified lead variants as covariates until we
667	did not detect any significant associations ($P < 5 \times 10^{-8}$).

668

669 Estimation of heritability and bias in GWAS results

We estimated heritability and confounding bias in EUR- and EAS-GWAS results with S-LDSC (version
1.0.0) using the baselineLD model (version 2.1). For EUR-GWAS, we utilized LD scores calculated in
EUR samples in 1KG Phase3. For EAS-GWAS, we utilized LD scores calculated in EAS samples in 1KG
Phase3. Since LDSC required a large sample size in GWAS (typically > 5K individuals), we restricted
this analysis to EUR- and EAS-GWAS. We estimated prevalence of RA was 0.5% in both ancestries.

675

676 Fine-mapping analysis

⁶⁷⁷ We conducted fine-mapping analysis using approximate Bayesian factor (ABF) and constructed 95% ⁶⁷⁸ credible set for each significant locus³⁵. We used trans-ancestry GWAS results. We included all the 122 ⁶⁷⁹ autosomal loci ($P < 5.0 \times 10^{-8}$). We calculated ABF of each variant according to equation (1):

$$ABF = \sqrt{\frac{SE^2}{SE^2 + \omega} exp\left[\frac{\omega\beta^2}{2SE^2(SE^2 + \omega)}\right]}$$

where β and *SE* are the variant's effect size and standard error, respectively; ω denotes the prior variance in allelic effects (we empirically set this value to be 0.04)⁷⁸. For each locus, we calculated posterior inclusion probability (PIP) of variant *k* according to equation (2):

$$PIP_k = \frac{ABF_k}{\sum_i ABF_i}$$

where *j* denotes all the variants included in the locus. We sorted all variants in order of decreasing PIP
and constructed 95% credible set including variants from the top PIP until the cumulative PIP reached
0.95. When we compared the fine-mapping resolution across different GWAS setting, we also applied
this fine-mapping strategy to EUR-GWAS and EAS-GWAS for all the 122 autosomal loci.

689

690 Functional interpretation of fine-mapped variants

We quantified the enrichment of the 95% credible set variants at the 113 autosomal loci within ATAC-seq peaks in 18 hematopoietic populations using gchromVAR software³⁷. We utilized the default parameters and ATAC-seq data processed by the developers. To access the specificity of a given ATAC-seq peak, we first normalized the read count of that peak in all 18 hematopoietic populations (each peak's read count was divided by the total read counts, scaled by 1000,000, added 1 as an offset value, and log2transformed), and transformed these 18 normalized counts into Z-scores.

697

698 Functional interpretation of associated variants

We inferred the possible molecular consequences of all 148 variants detected in this study. We first 699 focused on coding variants in LD with the lead variants in this GWAS ($r^2 > 0.6$ both in EUR and EAS) 700 samples in 1KG Phase 3; when the lead variant is monomorphic in one ancestry, we only utilized the 701 other ancestry). To annotate coding variants, we used ANNOVAR and assessed their potential impacts 702 on protein function; we reported SIFT and Polyphen2 (HDIV) scores. To interpret their effects on gene 703 regulation, we tested colocalization of our GWAS signals and eQTL or sQTL signals using coloc 704 software⁴⁰. We analyzed eQTL and sQTL results from Blueprint consortium database (CD4⁺ T cells, 705 monocytes, and neutrophils) and eQTL results from v7 GTEx project database (48 tissues)^{39,49}. Since 706 coloc assumes GWAS and QTL signals are obtained from the same ancestry group, we only used EUR-707

- ⁷⁰⁸ GWAS results for this analysis. We defined GWAS and QTL signals are colocalizated when the posterior
 ⁷⁰⁹ probability estimated by coloc software > 0.7.
- 710

711 Capture RNA-seq of PADI4 isoforms

We obtained total RNAs from THP-1 cells after stimulation with PMA for 72h, which induces the 712 expression of PADI4⁷⁹. We reverse-transcribed the RNA (10 ng) into cDNAs with Smart-seg2 primers⁸⁰. 713 and then amplified them by 10 cycles of polymerase chain reaction. We hybridized PADI4 isoforms with 714 xGen Lockdown Probes (5'-biotinylated 120-mer DNA probes synthesized by Integrated DNA 715 Technologies) designed for all exons of PADI4 main isoform. We captured the hybridized cDNAs with 716 streptavidin-conjugated magnetic beads and then sequenced them with MinION sequencer using LSK-717 109 kit (Oxford Nanopore Technologies). We analyzed the sequenced reads with FLAIR 718 (https://github.com/BrooksLabUCSC/flair). 719 We then performed sQTL analysis targeting PADI4 using the eQTL data of peripheral blood 720

subsets⁵. We reassembled and quantified the RNA-seq reads for *PADI4* isoforms including the newly
 discovered isoform using Cufflinks (http://cole-trapnell-lab.github.io/cufflinks/). We calculated the isoform
 ratio by dividing each isoform expression (FPKM) over total isoform expression. We used QTLtools
 (https://qtltools.github.io/qtltools/) for association testing.

725

726 Stratified linkage disequilibrium score regression

We conducted stratified LD score regression (S-LDSC) to partition heritability. For this analysis, we used 707 cell-type-specific IMPACT annotations and 396 histone mark annotations^{65,81}. IMPACT regulatory annotations were created by aggregating 5,345 epigenetic datasets to predict binding patterns of 142 transcription factors across 245 cell types. We computed annotation-specific LD scores using the EUR samples in 1KG Phase3 to analyze EUR-GWAS results. Similarly, we used EAS samples in 1KG Phase3 to analyze EAS-GWAS results. We estimated heritability enrichment of each annotation, while controlling for the 53 categories of the full baseline model. When we controlled the effect of an annotation, we

conducted the same S-LDSC analysis but additionally including that annotation in a single model. We
 excluded variants in the MHC region (chr6:25 Mb-35 Mb).

736

737 Trans-ancestry comparison of genetic signals

⁷³⁸ We first sought to compare the effect size estimates among GWAS results from each ancestry at the ⁷³⁹ lead variants. However, the lead variants are not always the causal variants, and hence we restricted our ⁷⁴⁰ targets to fine-mapped lead variants (*PIP* > 0.5). In addition, we excluded rare variants from this analysis ⁷⁴¹ because the effect sizes could not be accurately estimated for rare variants (MAF < 0.01 in either of the ⁷⁴² major ancestries in 1KG Phase 3). We finally included 30 fine-mapped variants for this analysis.

We next obtained trans-ancestry genetic-effect correlation using Popcorn software (version 1.0)⁶². We used summary statistics of EUR- and EAS-GWAS, and selected association statistics from variants with at least non-missing genotype from 5,000 individuals. We also excluded the MHC region from the analysis because of its complex LD structure. Using these post-QC summary statistics, we calculated the trans-ancestry genetic-effect correlation between EUR and EAS with precomputed cross-ancestry scores for EUR and EAS 1000 Genomes ancestries provided by the authors.

749

750 Polygenic risk score

We used the pruning and thresholding method to calculate PRS in this study. We developed PRS 751 models with six different conditions using combinations of two components; i) two variant selection 752 settings used for PRS ((a) all variants or (b) variants within top 5% of the CD4⁺ T cell T-bet IMPACT 753 annotation) and ii) three GWAS settings used for PRS (we used trans-ancestry, EUR-, or EAS-GWAS 754 and refer PRS based on each of them as trans-ancestry, EUR-, or EAS-PRS, respectively). We designed 755 our study so that the samples used in constructing PRS be independent from the samples in validation. 756 When we evaluated the PRS performance in a given cohort, we re-conducted GWAS meta-analysis 757 excluding that cohort to develop PRS models (Figure 6a). Before pruning, we removed rare variants 758 from three GWAS results to reduce unstable effect estimates in PRS (MAF < 0.01 in EUR samples of 759 1KG Phase3 for EUR- and trans-ancestry GWAS; and MAF < 0.01 in EAS samples of 1KG Phase3 for 760

EAS-GWAS). We also restricted this analysis to the variants which exist both in the GWAS results and 761 post-QC imputed genotype of a cohort for which we apply PRS; and then we selected variants based on 762 IMPACT annotation or utilized all variants (as described above). To LD-prune variants ($r^2 < 0.2$), we used 763 haplotype information in EUR samples of 1KG Phase3 for EUR- and trans-ancestry GWAS and EAS 764 samples of 1KG Phase3 for EAS-GWAS. For each of six conditions, we used 10 different P value 765 thresholds: 0.1, 0.03, 0.01, 0.003, 0.001, 3.0 x 10⁻⁴, 1.0 x 10⁻⁴, 3.0 x 10⁻⁵, 1.0 x 10⁻⁵, and 5.0 x 10⁻⁸; we 766 thus ended up having 60 different PRS models (6 conditions x 10 P value thresholds). We applied these 767 60 PRS models to 37 cohorts and applied a logistic regression model using per-individual PRS including 768 the same covariates as used in GWAS; we evaluated PRS performances by Nagelkerke R^2 . In each of 769 six PRS conditions, we selected the P value threshold with the largest average Nagelkerke R^2 , and used 770 this *P* value threshold for the following analyses. 771

To discuss the PRS distribution in an ancestry, we first calculated PRS in each cohort using a 772 specified condition; we next scaled those PRS values using the mean and the standard deviation of the 773 PRS only of the control samples in that cohort; and we then merged PRS values across cohorts in an 774 ancestry. We approximated the PRS distribution in general population by using that in control samples. 775 For a given PRS value (at the right tail of PRS distribution), we compared the case-control ratios 776 between individuals whose PRS is higher than that value and individuals whose PRS is lower than (or 777 equal to) that value and calculated the odds ratio; and we then identified the minimum PRS value which 778 showed odds ratio larger than three. 779

- 781 **Data availability:** The summary statistics and the PRS model with the best performance are publicly
- available at the following link:
- 783 https://data.cyverse.org/dav-anon/iplant/home/kazuyoshiishigaki/ra_gwas/ra_gwas-10-28-2021.tar.
- The codes are available at our website:
- 785 https://github.com/immunogenomics/RA GWAS.
- 786

787 Acknowledgement:

We thank the Director of Health Malaysia for supporting the work described in the South Asian (SAS): 788 the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA) study. The MyEIRA study 789 was funded by grant from Ministry of Health Malaysia (NMRR-08-820-1975) and the Swedish National 790 Research Council (DNR-348-2009-6468). The GENRA study and the CARDERA genetics cohort 791 genotyping were funded by Versus Arthritis (Grant Reference 19739 to ICS). The Nurses' Health Study 792 (NHS cohort) is funded by the NIH (R01 AR049880, UM1 CA186107, R01 CA49449, U01 CA176726, 793 and R01 CA67262). The Swedish EIRA study was supported by the Swedish Research Council (to LK. 794 LP and LA). SS was in part supported by The Mochida Memorial Foundation for Medical and 795 Pharmaceutical Research, Kanae Foundation for the promotion of medical science, Astellas Foundation 796 for Research on Metabolic Disorder, The JCR Grant for Promoting Basic Rheumatology, and Manabe 797 Scholarship Grant for allergic and rheumatic diseases. ICS is funded by the NIHR Advanced Research 798 Fellowship (Grant Reference NIHR300826). The views expressed are those of the author(s) and not 799 necessarily those of the NIHR or the Department of Health and Social Care. KAS is supported by the 800 Sherman Family Chair in Genomic Medicine and by a Canadian Institutes for Health Research 801 Foundation grant (FDN 148457) and grants from the Ontario Research Fund (RE-09-090) and Canadian 802 Foundation for Innovation(33374). S.Bae is supported by Basic Science Research Program through the 803 NRF funded by the Ministry of Education (NRF-2021R1A6A1A03038899). RPK and JCE are funded by 804 NIH (UL1 TR003096). CML is part-funded by the National Institute for Health Research (NIHR) Maudsley 805 Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College 806 London. T.Arayssi was partially supported by the National Priorities Research Program (grant 4-344-3-807

105 from the Qatar National Research Fund, a member of Qatar Foundation). M.Kerick and JM are
funded by Rheumatology Cooperative Research Thematic Network programme RD16/0012/0013 from
the Instituto de Salud Carlos III (ISCIII, Spanish Ministry of Science and Innovation). YO is funded by
JSPS KAKENHI (19H01021, 20K21834), AMED (JP21km0405211, JP21ek0109413, JP21ek0410075,
JP21gm4010006, and JP21km0405217), JST Moonshot R&D (JPMJMS2021, JPMJMS2024), Takeda
Science Foundation, Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka
University.

815

816 Author contributions:

K.Ishigaki, SS, C.Terao, YO, and S.Raychaudhuri conceived and designed the study. K.Ishigaki wrote

the manuscript with critical inputs from SS, C.Terao, YL, YO, and S.Raychaudhuri. K.Ishigaki conducted

meta-analysis and all GWAS downstream analyses with the help of SS, C.Terao, T.Amariuta, YL, YO,

and S.Raychaudhuri. K.Yamaguchi and Y.Kochi conducted PADI4 long-read sequencing and PADI4

sQTL analysis. M.Koido, KT, Y.Kamatani, and C.Terao contributed to construction of population-specific

reference panel. K.Ishigaki, SS, C.Terao, KS, VAL, ICS, SV, DP, JB, GX, JZ, CA, EK, RJC, KAS,

M.Kerick, FM, M.Traylor, CML, HX, RS, T.Arayssi, JM, LK, YO, and S.Raychaudhuri conducted GWAS.

C.Terao, CL.Too, VAL, SV, M.Takahashi, XW, LL, FL, DP, AB, GO, JB, SM, KPL, RJC, EWK, K.Matsuo,

FM, SE, HX, K.Ikari, PKG, LP, YO, and S.Raychaudhuri contributed to genotyping experiments. C.Terao,

KS, CL.Too, VAL, ICS, SV, KO, AM, MH, HI, M.Hammoudeh, SA, BKM, HH, HB, IWU, XW, LL, FL, DP,

AB, GO, SMV, AJM, SH, HT, ET, AS, YM, Kenichi Yamamoto, SM, GX, JZ, CA, EK, GW, IvH, JC, KPL,

RJC, HL, S.Bang, KAS, Nd, LA, S.Rantapää-Dahlqvist, EWK, S.Bae, RPK, JCE, XM, TH, PD, MS,

M.Kerick, JCD, The Biobank Japan Project, K.Matsuda, K.Matsuo, TM, FM, KF, YT, AK, CML, SE, HX,

RS, T.Arayssi, K.Ikari, M.Harigai, PKG, Kazuhiko Yamamoto, SLB, LP, JM, LK, YO, and S.Raychaudhuri

contributed to collection of samples and management of genotype data and clinical information.

832

833 Competing interests:

⁸³⁴ The authors declare no competing interests.

Reference:

- Ajeganova, S. & Huizinga, T. W. J. Seronegative and seropositive RA: alike but different? *Nat. Rev. Rheumatol. 2014 111* **11**, 8–9 (2014).
- Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **506**, 376–381 (2014).
- Ishigaki, K. *et al.* Large-scale genome-wide association study in a Japanese population identifies
 novel susceptibility loci across different diseases. *Nat. Genet.* 52, 669–679 (2020).
- 4. MacGregor, A. J. *et al.* Characterizing the quantitative genetic contribution to rheumatoid arthritis
 using data from twins. *Arthritis Rheum.* 43, 30–37 (2000).
- Ishigaki, K. *et al.* Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid
 arthritis. *Nat. Genet.* **49**, 1120–1125 (2017).
- Westra, H. J. *et al.* Fine-mapping and functional studies highlight potential causal variants for
 rheumatoid arthritis and type 1 diabetes. *Nat. Genet.* **50**, 1366–1374 (2018).
- Trynka, G. *et al.* Chromatin marks identify critical cell types for fine mapping complex trait variants.
 Nat. Genet. **45**, 124–30 (2013).
- 851 8. Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and Rigorous
- ⁸⁵² Computation of Gene and Pathway Scores from SNP-Based Summary Statistics. *PLoS Comput.* ⁸⁵³ *Biol.* **12**, 1–20 (2016).
- Ishigaki, K. *et al.* HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors.
 medRxiv (2020). doi:https://doi.org/10.1101/2020.11.08.20227983
- Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
 association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- Asgari, S. *et al.* A positively selected FBN1 missense variant reduces height in Peruvian
 individuals. *Nature* 582, 234–239 (2020).
- Estrada, K. *et al.* Association of a low-frequency variant in HNF1A with type 2 diabetes in a latino
 population the SIGMA Type 2 Diabetes Consortium. *JAMA* **311**, 2305–2314 (2014).
- 13. Moltke, I. et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and

- type 2 diabetes. *Nature* **512**, 190–193 (2014).
- Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify distinct
 and shared genetic risk loci for coronary artery disease. *Nat. Genet.* 52, 1169–1177 (2020).
- ⁸⁶⁶ 15. Chen, M. H. *et al.* Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals
 ⁸⁶⁷ from 5 Global Populations. *Cell* **182**, 1198-1213.e14 (2020).
- Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature* 547, 173–178 (2017).
- Laufer, V. A. *et al.* Genetic influences on susceptibility to rheumatoid arthritis in African Americans. *Hum. Mol. Genet.* 28, 858–874 (2019).
- Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities.
 Nat. Genet. **51**, 584–591 (2019).
- Ruan, Y. *et al.* Improving Polygenic Prediction in Ancestrally Diverse Populations. *medRxiv* 2020.12.27.20248738 (2021). doi:10.1101/2020.12.27.20248738
- Márquez-Luna, C. *et al.* Multiethnic polygenic risk scores improve risk prediction in diverse
 populations. *Genet. Epidemiol.* 41, 811–823 (2017).
- Leng, R. X. *et al.* Identification of new susceptibility loci associated with rheumatoid arthritis. *Ann. Rheum. Dis.* **79**, 1565–1571 (2020).
- 880 22. Kochi, Y. et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with
- rheumatoid arthritis and several autoimmunities. *Nat. Genet.* **37**, 478–85 (2005).
- Suzuki, A. *et al.* Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine
 deiminase 4, are associated with rheumatoid arthritis. *Nat. Genet.* **10**, 520–527 (2003).
- Okada, Y. *et al.* Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the
 Japanese population. *Nat. Genet.* 44, 511–516 (2012).
- 25. Diogo, D. et al. TYK2 protein-coding variants protect against rheumatoid arthritis and
- autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.
 PLoS One **10**, 1–21 (2015).
- 26. Traylor, M. et al. Genetic associations with radiological damage in rheumatoid arthritis: Meta-

890		analysis of seven genome-wide association studies of 2,775 cases. PLoS One 14, (2019).
891	27.	Márquez, A. et al. Meta-analysis of Immunochip data of four autoimmune diseases reveals novel
892		single-disease and cross-phenotype associations. Genome Med. 10, 97 (2018).
893	28.	Wei, W. H., Viatte, S., Merriman, T. R., Barton, A. & Worthington, J. Genotypic variability based
894		association identifies novel non-additive loci DHCR7 and IRF4 in sero-negative rheumatoid
895		arthritis. <i>Sci. Rep.</i> 7 , (2017).
896	29.	Márquez, A. et al. A combined large-scale meta-Analysis identifies COG6 as a novel shared risk
897		locus for rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 76, 286–294
898		(2017).
899	30.	Bossini-Castillo, L. et al. A genome-wide association study of rheumatoid arthritis without
900		antibodies against citrullinated peptides. Ann. Rheum. Dis. 74, (2015).
901	31.	Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid
902		arthritis. Nat. Genet. 44, 1336–1340 (2012).
903	32.	acosta-Herrera, M. et al. Genome-wide meta-analysis reveals shared new loci in systemic
904		seropositive rheumatic diseases. Ann Rheum Dis 78, 311–319 (2019).
905	33.	Frisell, T. et al. Familial risks and heritability of rheumatoid arthritis: Role of rheumatoid factor/anti-
906		citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis
907		Rheum. 65 , 2773–2782 (2013).
908	34.	Padyukov, L. et al. A genome-wide association study suggests contrasting associations in ACPA-
909		positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259–265 (2011).
910	35.	Maller, J. B. et al. Bayesian refinement of association signals for 14 loci in 3 common diseases.
911		Nat. Genet. 44, 1294–1301 (2012).
912	36.	Kichaev, G. & Pasaniuc, B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-Mapping
913		Studies. Am. J. Hum. Genet. 97, 260–271 (2015).
914	37.	Ulirsch, J. C. et al. Interrogation of human hematopoiesis at single-cell and single-variant
915		resolution. <i>Nat. Genet.</i> 51 , 683–693 (2019).
916	38.	Fu, W. et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of

⁹¹⁷ regulatory T cells. *Nat. Immunol.* **13**, 972–980 (2012).

- 39. Chen, L. *et al.* Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune
 Cells. *Cell* **167**, 1398-1414.e24 (2016).
- Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association
 Studies Using Summary Statistics. *PLoS Genet.* **10**, (2014).
- Ferreira, R. C. *et al.* Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and
 Influences Risk of Diverse Inflammatory Diseases. *PLoS Genet.* 9, e1003444 (2013).
- 924 42. Okada, Y. *et al.* Significant impact of miRNA–target gene networks on genetics of human complex
 925 traits. *Sci. Reports 2016 61* 6, 1–9 (2016).
- 43. Schellekens, G. A., De Jong, B. A. W., Van Den Hoogen, F. H. J., Van De Putte, L. B. A. & Van

⁹²⁷ Venrooij, W. J. Citrulline is an essential constituent of antigenic determinants recognized by

rheumatoid arthritis-specific autoantibodies. *J. Clin. Invest.* **101**, 273–281 (1998).

- Suzuki, A. *et al.* Decreased severity of experimental autoimmune arthritis in peptidylarginine
 deiminase type 4 knockout mice. *BMC Musculoskelet. Disord.* 17, (2016).
- 45. Seri, Y. *et al.* Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose6-phosphate isomerase-induced arthritis model. *Sci. Rep.* 5, 1–10 (2015).
- 46. Arita, K. *et al.* Structural basis for Ca2+-induced activation of human PAD4. *Nat. Struct. Mol. Biol.*11, 777–783 (2004).
- 47. Nanda, S. K. *et al.* ABIN2 Function Is Required To Suppress DSS-Induced Colitis by a Tpl2Independent Mechanism. *J. Immunol.* 201, 3373–3382 (2018).
- Matmati, M. *et al.* A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis
 resembling rheumatoid arthritis. *Nat. Genet.* 43, 908–912 (2011).
- 49. Aguet, F. *et al.* Genetic effects on gene expression across human tissues. *Nature* 550, 204–213
 (2017).
- 50. James, E. A. *et al.* Citrulline-Specific Th1 Cells Are Increased in Rheumatoid Arthritis and Their
 Frequency Is Influenced by Disease Duration and Therapy. *Arthritis Rheumatol.* 66, 1712–1722
 (2014).

- 51. Takayanagi, H. *et al.* RANKL maintains bone homeostasis through c-fos-dependent induction of
 interferon-β. *Nature* **416**, 744–749 (2002).
- 52. Takeuchi, T. et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in
- patients with rheumatoid arthritis treated with conventional synthetic disease-modifying
- ⁹⁴⁸ antirheumatic drugs (DESIRABLE study): A randomised, double-blind, placebo-controlled phase.
- Ann. Rheum. Dis. **78**, 899–907 (2019).
- 53. Nakatsuka, K., Nishizawa, Y. & Ralston, S. H. Phenotypic characterization of early onset Paget's
- disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. *J. Bone Miner. Res.* 18,
 1381–1385 (2003).
- 54. Osterberg, P. H. *et al.* Familial expansile osteolysis. A new dysplasia. *J. Bone Jt. Surg. Ser. B*70, 255–260 (1988).
- ⁹⁵⁵ 55. Guerrini, M. M. *et al.* Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to
 ⁹⁵⁶ TNFRSF11A (RANK) Mutations. *Am. J. Hum. Genet.* **83**, 64–76 (2008).
- ⁹⁵⁷ 56. French, D. M. *et al.* WISP-1 is an osteoblastic regulator expressed during skeletal development
 ⁹⁵⁸ and fracture repair. *Am. J. Pathol.* **165**, 855–867 (2004).
- 57. Maeda, A. *et al.* WNT1-Induced Secreted Protein-1 (WISP1), a novel regulator of bone turnover
 and Wnt signaling. *J. Biol. Chem.* **290**, 14004–14018 (2015).
- 58. Zhang, F. *et al.* Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by
- ⁹⁶² integrating single-cell transcriptomics and mass cytometry. *Nat. Immunol.* **20**, 928–942 (2019).
- ⁹⁶³ 59. Ramos, M. I. P. *et al.* Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects
 ⁹⁶⁴ against collagen-induced arthritis. *Ann. Rheum. Dis.* **74**, 211–219 (2015).
- Saevarsdottir, S. *et al.* FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune
 thyroid disease. *Nature* 584, 619–623 (2020).
- Motegi, T. *et al.* Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in
 the Japanese population and their effects on cytokine signalling. *Ann. Rheum. Dis.* **78**, 1062–1069
 (2019).
- 970 62. Brown, B. C., Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation Estimates from

971 Summary Statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).

- ⁹⁷² 63. Wiede, F. *et al.* CCR6 is transiently upregulated on B cells after activation and modulates the ⁹⁷³ germinal center reaction in the mouse. *Immunol. Cell Biol.* **91**, 335–339 (2013).
- 64. Lee, B. O. *et al.* CD40, but Not CD154, Expression on B Cells Is Necessary for Optimal Primary B
 975 Cell Responses. *J. Immunol.* **171**, 5707–5717 (2003).
- 65. Amariuta, T. *et al.* Improving the trans-ancestry portability of polygenic risk scores by prioritizing
 variants in predicted cell-type-specific regulatory elements. *Nat. Genet.* **52**, 1346–1354 (2020).
- 66. Amariuta, T. et al. IMPACT: Genomic Annotation of Cell-State-Specific Regulatory Elements
- Inferred from the Epigenome of Bound Transcription Factors. *Am. J. Hum. Genet.* **104**, 879–895
 (2019).
- ⁹⁸¹ 67. Chun, S. *et al.* Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-

disease-associated loci in three major immune-cell types. *Nat. Genet.* **49**, 600–605 (2017).

- 68. Van Der Wijst, M. G. P. *et al.* Single-cell RNA sequencing identifies celltype-specific cis-eQTLs
 and co-expression QTLs. *Nat. Genet.* **50**, 493–497 (2018).
- 69. Kumasaka, N., Knights, A. J. & Gaffney, D. J. High-resolution genetic mapping of putative causal
 interactions between regions of open chromatin. *Nat. Genet.* **51**, 128–137 (2019).
- ⁹⁸⁷ 70. Gutierrez-Arcelus, M. *et al.* Allele-specific expression changes dynamically during T cell activation
 ⁹⁸⁸ in HLA and other autoimmune loci. *Nat. Genet.* **52**, 247–253 (2020).
- P89 71. Baglaenko, Y., Macfarlane, D., Marson, A., Nigrovic, P. A. & Raychaudhuri, S. Genome editing to
 define the function of risk loci and variants in rheumatic disease. *Nat. Rev. Rheumatol.* **17**, 462–
 474 (2021).
- Arnett, F. C. *et al.* The american rheumatism association 1987 revised criteria for the classification
 of rheumatoid arthritis. *Arthritis Rheum.* **31**, 315–324 (1988).
- Aletaha, D. *et al.* 2010 Rheumatoid arthritis classification criteria: An American College of
 Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis and Rheumatism* 62, 2569–2581 (2010).
- 997 74. Akiyama, M. et al. Characterizing rare and low-frequency height-associated variants in the

Japanese population. *Nat. Commun.* **10**, (2019).

- 75. Zhang, W. *et al.* Whole genome sequencing of 35 individuals provides insights into the genetic
 architecture of Korean population. *BMC Bioinformatics* **15**, (2014).
- 1001 76. Lan, T. *et al.* Deep whole-genome sequencing of 90 Han Chinese genomes. *Gigascience* 6,
 1002 (2017).
- 1003 77. Wong, L. P. *et al.* Deep whole-genome sequencing of 100 southeast Asian malays. *Am. J. Hum.*1004 *Genet.* 92, 52–66 (2013).
- 1005 78. Wakefield, J. A bayesian measure of the probability of false discovery in genetic epidemiology
 1006 studies. *Am. J. Hum. Genet.* 81, 208–227 (2007).
- Rumble, J. M., Fackelman, E. M. & Mobley, J. L. Comparative analyses of PAD expression and
 activity in myeloid cell lines. *J. Immunol.* **198**, (2017).
- 1009 80. Picelli, S. *et al.* Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protoc.* 2013 91 9,
 1010 171–181 (2014).
- Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).